natgillin/translations-raw huggingface dataset:
What is happening for Zavesca for the treatment of type 1 Gaucher disease? 
Kakšne so posledice za zdravilo Zavesca, indicirano za zdravljenje Gaucherjeve bolezni tipa 1?
Zavesca was designated as an orphan medicinal product on 16 February 2006 for Niemann Pick type C disease. 
Zdravilo Zavesca je bilo dne 16. februarja 2000 določeno kot zdravilo sirota za zdravljenje NiemannPick-ove bolezni tipa C.
It is used for the treatment of mild to moderate type 1 Gaucher disease. 
Zdravilo Zavesca je namenjeno za zdravljenje blage do zmerne oblike Gaucherjeve bolezni tipa 1.
The study compared the effects of adding Zavesca taken at a dose of 200 mg three times a day to standard care with the effects of standard care alone. 
Učinkovitost zdravila Zavesca so preučevali v eni glavni študiji, ki je vključevala 29 bolnikov v starosti 12 let in več z Niemann-Pick-ovo boleznijo tipa C. V okviru študije so primerjali učinek dodajanja zdravila Zavesca v odmerku 200 mg trikrat dnevno k standardnemu zdravljenju z učinkom standardnega zdravljenja samega.
Therefore, at that point in time, the CHMP was of the opinion that the benefits of Zavesca in the treatment of neurological manifestations in Niemann Pick type C disease did not outweigh its risks. 
CHMP je tedaj menil, da koristi zdravila Zavesca pri zdravljenju nevroloških simptomov NiemannPick-ove bolezni tipa C ne odtehtajo z njim povezanih tveganj.
How is Zavesca expected to work? 
Kako bi naj zdravilo Zavesca delovalo?
was the change in the speed at which the patients made saccadic horizontal eye movements after a year's treatment. 
Glavno merilo učinkovitosti je bila sprememba hitrosti, s katero je bolnik delal sunkovite vodoravne gibe z očmi.
‘Complicated' means that the infection is difficult to treat. 
„Zapletena“ pomeni, da je okužbo težko zdraviti.
The European Commission granted a marketing authorisation valid throughout the European Union for Tygacil on 24 April 2006. 
Evropska komisija je dovoljenje za promet z zdravilom Tygacil, veljavno po vsej Evropski uniji, izdala 24. aprila 2006.
Treatment lasts from 5 to 14 days. 
Zdravljenje traja od pet do 14 dni.
The full EPAR for Tygacil can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tygacil je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
What measures are being taken to ensure the safe and effective use of Tygacil? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Tygacil?
Each infusion should last between 30 and 60 minutes. 
Posamezna infuzija naj traja od 30 do 60 minut.
What benefit has Tygacil shown during the studies? 
Kakšne koristi je zdravilo Tygacil izkazalo med študijami?
By blocking the production of new proteins, the bacteria cannot multiply and they eventually die. 
Z zaviranjem tvorbe novih beljakovin se bakterije ne morejo več razmnoževati in sčasoma odmrejo.
The length of treatment depends on where the infection is, how severe it is, and the patient's response to treatment. 
Trajanje zdravljenja je odvisno od mesta okužbe, resnosti okužbe ter od bolnikovega odziva na zdravljenje.
In all of the studies, the main measure of effectiveness was the number of patients whose infection was cured. 
Glavno merilo učinkovitosti v vseh teh študijah je bilo število bolnikov, pri katerih se je okužba pozdravila.
The CHMP decided that Tygacil's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Tygacil večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
It is also used to treat complicated infections in the abdomen. 
Uporablja se tudi za zdravljenje zapletenih trebušnih okužb.
This document is a summary of the European Public Assessment Report (EPAR) for Tygacil. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Tygacil.
Patients allergic to tetracycline antibiotics may also be allergic to Tygacil. 
Bolniki, ki so alergični na tetraciklinske antibiotike, utegnejo biti alergični tudi na zdravilo Tygacil.
Before using Tygacil, doctors should consider official guidance on the appropriate use of antibiotics. 
Preden zdravnik predpiše zdravilo Tygacil, mora upoštevati uradne smernice za ustrezno uporabo antibiotikov.
For more information about treatment with Tygacil, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Tygacil preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that Tygacil is used as safely and effectively as possible. 
Za zagotovitev čim varnejše in učinkovitejše uporabe zdravila Tygacil je bil pripravljen načrt obvladovanja tveganj.
It works by blocking the bacteria's ribosomes, the parts of the cell where new proteins are made. 
Deluje tako, da zavira ribosome bakterij oziroma tiste dele celic, ki proizvajajo nove beljakovine.
Tygacil should be used only when other antibiotics are not suitable. 
Zdravilo Tygacil se lahko uporablja samo, kadar zdravljenje z drugimi antibiotiki ni primerno.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tygacil. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What is the risk associated with Tygacil? 
Kakšna tveganja so povezana z zdravilom Tygacil?
Tygacil has been compared with other antibiotics in four main studies. 
Zdravilo Tygacil so z drugimi antibiotiki primerjali v štirih glavnih študijah.
Other information about Tygacil: 
Druge informacije o zdravilu Tygacil:
The list of bacteria against which Tygacil is active can be found in the summary of product characteristics (also part of the EPAR). 
Seznam bakterij, proti katerim zdravilo Tygacil učinkuje, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako sestavni del EPAR).
Although there are few data in children, studies suggest that Tygacil can be a treatment alternative for complicated skin and soft tissue or abdominal infections, with bacteria resistant to other antibiotics. 
Čeprav je za zdravljenje otrok na voljo le malo podatkov, študije kažejo, da je zdravilo Tygacil lahko alternativno zdravilo za zapletene okužbe kože in mehkih tkiv ali okužbe trebušne votline, kadar so bakterije odporne proti drugim antibiotikom.
Tygacil must not be used in people who are hypersensitive (allergic) to tigecycline or any of the other ingredients. 
Zdravila Tygacil ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) tigeciklin ali katero koli drugo sestavino zdravila.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tygacil, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Why has Tygacil been approved? 
Zakaj je bilo zdravilo Tygacil odobreno?
In the four main studies, Tygacil was as effective as the comparator antibiotics. 
V štirih glavnih študijah je bilo zdravilo Tygacil enako učinkovito kot primerjalni antibiotiki.
Tygacil is used to treat adults and children older than eight years with complicated infections of the skin and soft tissue (the tissue below the skin), but not foot infections in people with diabetes. 
Zdravilo Tygacil se uporablja za zdravljenje odraslih in otrok, starejših od osem let, z zapletenimi okužbami kože in mehkih (podkožnih) tkiv, vendar ne za zdravljenje okužb stopal pri bolnikih s sladkorno boleznijo.
The active substance in Tygacil, tigecycline, belongs to a group of antibiotics called ‘glycylcyclines'. 
Zdravilna učinkovina zdravila Tygacil, tigeciklin, spada v skupino antibiotikov, imenovanih „glicilciklini“.
In children from 12 to 18 years a dose of 50 mg is given every 12 hours for a period of 5 to 14 days. 
Pri otrocih, starih od 12 do 18 let, se vsakih 12 ur daje 50-miligramski odmerek pet do 14 dni.
In the other two studies, Tygacil was compared with imipenem/cilastatin (a combination of two medicines used together as an antibiotic) in 1,568 patients with complicated infections in the abdomen. 
V drugih dveh študijah so ga primerjali z imipenemom/cilastatinom (kombinacijo dveh zdravil, ki se uporablja kot antibiotik) pri 1 568 bolnikih z zapletenimi trebušnimi okužbami.
The most common side effects with Tygacil are mild to moderate nausea (feeling sick) and vomiting, seen in 20% and 14% of patients, respectively. 
Najpogostejša neželena učinka zdravila Tygacil sta blaga do zmerna navzeja (slabost) in bruhanje, ki sta bila opažena pri 20 % oziroma 14 % bolnikov.
It contains the active substance tigecycline. 
Vsebuje zdravilno učinkovino tigeciklin.
In adults, the recommended dose of Tygacil is a starting dose of 100 mg, followed by 50 mg every 12 hours for five to 14 days. 
Pri odraslih je priporočeni začetni odmerek zdravila Tygacil 100 mg, temu pa sledi jemanje 50-miligramskega odmerka vsakih 12 ur pet do 14 dni.
Doses are lower in patients with severe liver problems. 
Pri bolnikih z resnimi obolenji jeter morajo biti odmerki ustrezno nižji.
In the studies of skin and soft tissue infections, around 86% of the patients receiving Tygacil were cured, compared with around 89% of those receiving vancomycin and aztreonam. 
V študijah okužb kože in mehkih tkiv se je pozdravilo okoli 86 % bolnikov, ki so prejemali zdravilo Tygacil, v primerjavi z 89 % bolnikov, ki so prejemali vankomicin in aztreonam.
In children above eight years of age, treatment is only given after consulting with a doctor with appropriate experience in the management of infectious diseases, and should be given as an infusion over a period of 60 minutes. 
Pri otrocih, starejših od osem let, se zdravljenje lahko uvede le po posvetu z zdravnikom, ki ima ustrezne izkušnje z zdravljenjem okužb.
In the study looking at diabetic foot infections, Tygacil was less effective than ertapenem: 78% of the patients receiving Tygacil were cured, compared with 83% of those receiving ertapenem. 
V študiji, v kateri so proučevali okužbe stopal kot posledico sladkorne bolezni, se je zdravilo Tygacil izkazalo za manj učinkovito od ertapenema: pozdravilo se je 78 % bolnikov, ki so prejemali zdravilo Tygacil, v primerjavi s 83 % bolnikov, ki so prejemali ertapenem.
In children from 8 to 12 years old a dose of 1.2 mg per kilogram body weight is given by infusion into a vein every twelve hours, up to a maximum dose of 50 mg every 12 hours. 
Pri otrocih, starih od osem do 12 let, se zdravilo daje vsakih dvanajst ur z infundiranjem v veno v odmerku 1,2 mg na kilogram telesne mase, vse do največjega možnega odmerka 50 mg vsakih 12 ur.
For the full list of all side effects reported with Tygacil, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Tygacil, glejte navodilo za uporabo.
An additional study compared Tygacil with the antibiotic ertapenem in 813 diabetic patients with moderate to severe foot infections. 
V dodatni študiji so zdravilo Tygacil primerjali z antibiotikom ertapenemom pri 813 bolnikih s sladkorno boleznijo in zmernimi do hudimi okužbami stopal.
In two of these studies, Tygacil was compared with the combination of vancomycin and aztreonam in 1,129 patients with complicated skin and soft tissue infections (not including infected diabetic foot ulcers). 
V dveh študijah so ga primerjali s kombinacijo vankomicina in aztreonama pri 1 129 bolnikih z zapletenimi okužbami kože in mehkih tkiv (razen razjed na stopalih kot posledice sladkorne bolezni).
Tygacil is a powder that is made up into a solution for infusion (drip into a vein). 
Zdravilo Tygacil je prašek za pripravo raztopine za infundiranje (kapalne infuzije v veno).
How does Tygacil work? 
Kako zdravilo Tygacil deluje?
In the studies of abdominal infection, around 86% of the patients receiving either Tygacil or imipenem/cilastatin were cured. 
V študijah trebušnih okužb se je pozdravilo okoli 86 % bolnikov, ki so prejemali zdravilo Tygacil oziroma kombinacijo imipenema/cilastatina.
What is Tygacil used for? 
Za kaj se zdravilo Tygacil uporablja?
How has Tygacil been studied? 
Kako je bilo zdravilo Tygacil raziskano?
How is Tygacil used? 
Kako se zdravilo Tygacil uporablja?
Patients over 65 years of age and patients who have problems with their liver or kidneys may need a lower starting dose of 5 mg per day. 
Bolniki, ki so stari več kot 65 let, in bolniki, ki imajo težave z jetri ali ledvicami, bodo morda potrebovali nižji začetni odmerek, ki znaša 5 mg na dan.
It is known as an ‘atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. 
Spada med „atipične“ antipsihotike, ker se razlikuje od starejših antipsihotikov, ki so na voljo že od petdesetih let minulega stoletja.
The European Commission granted a marketing authorisation valid throughout the EU for Zalasta to KRKA, d.d., Novo mesto on 27 September 2007. 
Evropska komisija je dovoljenje za promet z zdravilom Zalasta, veljavno po vsej Evropski uniji, odobrila družbi KRKA, d.d., Novo mesto dne 27. septembra 2007.
It is available as round, yellow tablets (2.5, 5, 7.5, 10, 15 and 20 mg) and as round, yellow ‘orodispersible' tablets (5, 7.5, 10, 15 and 20 mg). 
Na voljo je v obliki okroglih rumenih tablet (2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg in 20 mg) in okroglih rumenih „orodisperzibilnih“ tablet (5 mg, 7,5 mg, 10 mg, 15 mg in 20 mg).
Schizophrenia is a mental illness that has a number of symptoms including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). 
Shizofrenija je duševna bolezen s številnimi simptomi, ki vključujejo neorganizirano mišljenje in govor, halucinacije (bolnik vidi in sliši stvari, ki jih ni), sumničavost ter blodnje (zmotna prepričanja).
It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine. 
Domnevajo, da so koristni učinki olanzapina posledica blokiranja receptorjev za živčna prenašalca 5-hidroksitriptamin (imenovanega tudi serotonin) in dopamin.
The recommended starting dose of Zalasta depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day. 
Priporočeni začetni odmerek zdravila Zalasta je odvisen od bolezni, ki jo zdravimo: odmerek 10 mg na dan se uporablja pri shizofreniji in za preprečevanje maničnih epizod, odmerek 15 mg na dan pa se uporablja pri zdravljenju maničnih epizod, razen v primeru sočasne uporabe z drugimi zdravili, ko lahko začetni odmerek znaša 10 mg na dan.
It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment. 
Zdravilo se lahko uporablja tudi za preprečevanje ponovnega pojava teh epizod (ponovitve simptomov) pri odraslih z bipolarno motnjo (duševno boleznijo, pri kateri se izmenjujejo obdobja privzdignjenega razpoloženja in depresije), ki so se odzvali na začetno zdravljenje.
This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other. 
S tem se prekine prenos signalov med možganskimi celicami preko „živčnih prenašalcev“, kemičnih snovi, ki jih živčne celice uporabljajo za medsebojno sporočanje.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ZALASTA EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) ZALASTA Povzetek EPAR za javnost
Zalasta is also effective in maintaining improvement in patients who have responded to an initial course of treatment. 
Zdravilo Zalasta je prav tako učinkovito pri vzdrževanju izboljšanja stanja pri bolnikih, ki so se odzvali na začetno zdravljenje.
The full EPARs for the reference medicines can also be found on the EMEA's website. 
Celotno evropsko javno poročilo o oceni zdravila za referenčni zdravili je na voljo na spletni strani agencije EMEA.
This means that Zalasta is similar to ‘reference medicines' already authorised in the European Union (EU) called Zyprexa and Zyprexa Velotab. 
To pomeni, da je podobno „referenčnima zdraviloma“, ki sta že odobreni v Evropski uniji (EU), in sicer zdravilu Zyprexa in zdravilu Zyprexa Velotab.
Because Zalasta is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicines (i.e. that the medicines produce the same levels of the active substance in the body). 
Ker je zdravilo Zalasta generično zdravilo, so bile študije omejene na teste, s katerimi se lahko dokaže, da je bioekvivalentno referenčnima zdraviloma (to pomeni, da omenjena zdravila dosegajo enake ravni zdravilne učinkovine v telesu).
Why has Zalasta been approved? 
Zakaj je bilo zdravilo Zalasta odobreno?
Zalasta is also used to treat moderate to severe manic episodes (extremely high mood) in adults. 
Zdravilo Zalasta se uporablja tudi za zdravljenje zmernih do težkih maničnih epizod (izjemno privzdignjenega razpoloženja) pri odraslih.
Zalasta is used to treat adults with schizophrenia. 
Zdravilo Zalasta se uporablja za zdravljenje odraslih s shizofrenijo.
What are the benefit and risk of Zalasta? 
Kakšne so koristi in tveganja, povezana z zdravilom Zalasta?
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Zalasta has been shown to have comparable quality and to be bioequivalent to Zyprexa and Zyprexa Velotab. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v s skladu z zahtevami EU dokazano, da ima zdravilo Zalasta primerljivo raven kakovosti kot zdravili Zyprexa in Zyprexa Velotab ter da je njun bioekvivalent.
The Committee recommended that Zalasta be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Zalasta odobri dovoljenje za promet.
Because Zalasta is a generic medicine and is bioequivalent to the reference medicines, its benefit and risk are taken as being the same as those of the reference medicines. 
Ker je Zalasta generično zdravilo in je biološko enakovredno referenčnima zdraviloma, se domneva, da ima enake koristi in tveganja kot referenčni zdravili.
Other information about Zalasta: 
Druge informacije o zdravilu Zalasta:
Zalasta is a ‘generic medicine'. 
Zdravilo Zalasta je „generično zdravilo“.
Zalasta is a medicine containing the active substance olanzapine. 
Zalasta je zdravilo, ki vsebuje zdravilno učinkovino olanzapin.
The orodispersible tablets, which can be used as an alternative to the tablets, are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing. 
Razpon odmerkov je običajno od 5 do 20 mg na dan. Orodisperzibilne tablete, ki se lahko uporabijo kot alternativa tabletam, se zaužijejo tako, da se jih položi na jezik, kjer jih slina hitro raztopi, ali tako, da se jih pred zaužitjem zmeša z vodo.
What is Zalasta used for? 
Za kaj se zdravilo Zalasta uporablja?
The active substance in Zalasta, olanzapine, is an antipsychotic medicine. 
Zdravilna učinkovina zdravila Zalasta, olanzapin, je antipsihotično zdravilo.
Therefore, the CHMP's view was that, as for Zyprexa and Zyprexa Velotab, the benefit outweighs the identified risk. 
Zaradi tega je CHMP menil, da koristi zdravila Zalasta tako kot pri zdravilih Zyprexa in Zyprexa Velotab odtehtajo znana tveganja.
How has Zalasta been studied? 
Kako je bilo zdravilo Zalasta raziskano?
How does Zalasta work? 
Kako zdravilo Zalasta deluje?
How is Zalasta used? 
Kako se zdravilo Zalasta uporablja?
The full EPAR for Zalasta can be found here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zalasta je na voljo tukaj.
The main measure of effectiveness was the number of patients who had responded to treatment after 12 weeks. 
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se po 12 tednih odzvali na zdravljenje.
It is given six to nine times a day. 
Zdravilo se daje šest- do devetkrat dnevno.
The recommended dose is 2.5 or 5 micrograms. 
Priporočeni odmerek je 2,5 ali 5 mikrogramov.
The European Commission granted a marketing authorisation valid throughout the European Union for Ventavis on 16 September 2003. 
Evropska komisija je dovoljenje za promet z zdravilom Ventavis, veljavno po vsej Evropski uniji, izdala 16. septembra 2003.
As the company had supplied the additional information requested at the time of authorisation, the ‘exceptional circumstances' ended on 26 August 
Ker je družba predložila dodatne informacije, zahtevane ob odobritvi, so izjemne okoliščine prenehale veljati 26. avgusta 2013.
The full EPAR for Ventavis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ventavis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
What measures are being taken to ensure the safe and effective use of Ventavis? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ventavis?
Ventavis was originally authorised under ‘exceptional circumstances' because, as the disease is rare, limited information was available at the time of approval. 
Zdravilo Ventavis je bilo prvotno odobreno v „izjemnih okoliščinah“, saj so bile zaradi redkosti bolezni ob odobritvi dovoljenja na voljo le omejene informacije.
This is a summary of the European public assessment report (EPAR) for Ventavis. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ventavis.
By dilating these blood vessels, the blood pressure is reduced and symptoms are improved. 
Z razširitvijo krvnih žil se krvni tlak zmanjša, simptomi pa se izboljšajo.
Ventavis was significantly more effective than placebo: 17% of the patients taking Ventavis responded to treatment (17 out of 101), compared with 5% of the patients taking placebo (5 out of 102). 
Zdravilo Ventavis je bilo znatno učinkovitejše od placeba: na zdravljenje se je odzvalo 17 % (17 od 101) bolnikov, ki so jemali zdravilo Ventavis, v primerjavi s 5 % (5 bolnikov od 102), ki so jemali placebo.
If the patient has liver or kidney problems, the time between doses should be at least three to four hours. 
Pri bolnikih z obolenji jeter ali ledvic mora biti premor med odmerkoma vsaj tri do štiri ure.
The CHMP decided that Ventavis's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Ventavis večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The dose should be reduced to 2.5 micrograms again if the patient cannot tolerate the higher dose. 
Odmerek se lahko nato ponovno zniža na 2,5 mikrograma, če bolnik višjega odmerka ne prenaša.
For more information about treatment with Ventavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Ventavis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.